Lv11
100 积分 2021-11-19 加入
Visual Acuity Gain With Ranibizumab Therapy: Two-Year Data From the Marina, Anchor, and Pier Trials in Patients With Neovascular Amd
5小时前
已关闭
Angiographic and Optical Coherence Tomographic Results of the MARINA Study of Ranibizumab in Neovascular Age-Related Macular Degeneration
5小时前
已完结
Conbercept for Treatment of Neovascular Age-related Macular Degeneration: Results of the Randomized Phase 3 PHOENIX Study
6小时前
已完结
Intravitreal Aflibercept (VEGF Trap-Eye) in Wet Age-related Macular Degeneration
6小时前
已完结
Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials
6小时前
已完结
HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration
6小时前
已完结
Cancer statistics 2024: All hands on deck
10天前
已完结
Incidence of patients with bone metastases at diagnosis of solid tumors in adults: a large population-based study
1个月前
已完结
COLUMBUS 7-year update: A randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF V600E/K-mutant melanoma
3个月前
已完结
A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor
3个月前
已完结
皖公网安备34019202002308
